• 1
    Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010; 8: 41.
  • 2
    March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 54451.
  • 3
    Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006; 166: 20816.
  • 4
    Björntorp P. Metabolic implications of body fat distribution. Diab Care 1991; 14: 113243.
  • 5
    Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595607.
  • 6
    Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56: 4562.
  • 7
    Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004; 59: 14154.
  • 8
    Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 1990; 32: 21320.
  • 9
    Kulshreshtha B, Ganie MA, Praveen EP, et al. Insulin response to oral glucose in healthy, lean young women and patients with polycystic ovary syndrome. Gynecol Endocrinol 2008; 24: 63743.
  • 10
    Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2008; 69: 63441.
  • 11
    Yilmaz M, Bukan N, Demirci H, et al. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25: 24652.
  • 12
    González F, Rote NS, Minium J, Kirwan JP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism 2009; 58: 95462.
  • 13
    Fornes R, Ormazabal P, Rosas C, et al. Changes in the expression of insulin signaling pathway molecules in endometria from polycystic ovary syndrome women with or without hyperinsulinemia. Mol Med 2010; 16: 12936.
  • 14
    Peppa M, Koliaki C, Nikolopoulos P, Raptis SA. Skeletal muscle insulin resistance in endocrine disease. J Biomed Biotechnol 2010; 2010: 527850.
  • 15
    Mukherjee S, Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res 2010; 131: 74360.
  • 16
    Tominaga K, Fujimoto E, Suzuki K, Hayashi M, Ichikawa M, Inaba Y. Prevalence of nonalcoholicfatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ Health Prev Med 2009; 14: 1429.
  • 17
    Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleveland Clin J Med 2008; 75: 7218.
  • 18
    Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 96974.
  • 19
    Kim HK, Park JY, Lee KU, et al. Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. Am J Med Sci 2009; 337: 98102.
  • 20
    Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 2348.
  • 21
    Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010; 59: 14105.
  • 22
    Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 2741.
  • 23
    Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16: 4217.
  • 24
    Collantes RS, Ong JP, Younossi ZM. The metabolic syndrome and nonalcoholic fatty liver disease. Panminerva Med 2006; 48: 418.
  • 25
    Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009; 104: 8617.
  • 26
    Brown AJ, Tendler DA, McMurray RG, Setji TL. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocr Pract 2005; 11: 31924.
  • 27
    Vassilatou E, Lafoyianni S, Vryonidou A, et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 2010; 25: 21220.
  • 28
    Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007; 5: 496501.
  • 29
    Cerda C, Pérez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007; 47: 4127.
  • 30
    Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 17417.
  • 31
    Brzozowska MM, Ostapowicz G, Weltman MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 2009; 24: 2437.
  • 32
    Markou A, Androulakis II, Mourmouris C, et al. Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertil Steril 2010; 93: 12206.
  • 33
    Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 2007; 104: 1258794.
  • 34
    Jornayvaz FR, Samuel VT, Shulman GI. The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. Annu Rev Nutr 2010; 30: 27390.
  • 35
    McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004; 53: 4959.
  • 36
    Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45: 6006.
  • 37
    Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010; 25: 67290.
  • 38
    Lunde O, Magnus P, Sandvik L, Hoglo S. Familial clustering in the polycystic ovarian syndrome. Gynec Obstet Invest 1989; 28: 2330.
  • 39
    Givens JR. Familial polycystic ovarian disease. Endocr Metab Clin N Am 1988; 17: 77183.
  • 40
    Simoni M, Tempfer CB, Destenaves B, Fauser BC. Functional genetic polymorphisms and female reproductive disorders: Part I: polycystic ovary syndrome and ovarian response. Hum Reprod Update 2008; 14: 45984.
  • 41
    Unluturk U, Harmanci A, Kocaefe C, Yildiz BO. The genetic basis of the polycystic ovary syndrome: a literature review including discussion of PPAR-gamma. PPAR Res 2007; 2007: 49109.
  • 42
    Goodarzi MO, Xu N, Cui J, Guo X, Chen YI, Azziz R. Small glutamine-rich tetratricopeptide repeat containing protein alpha (SGTA), a candidate gene for polycystic ovary syndrome. Hum Reprod 2008; 23: 12149.
  • 43
    Tan S, Scherag A, Janssen OE, et al. Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). BMC Med Genet 2010; 11: 12.
  • 44
    Cortón M, Botella-Carretero JI, Benguria A, et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 32837.
  • 45
    Glintborg D, Andersen M, Hagen C, et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 2006; 155: 33745.
  • 46
    Mohamed-Hussein ZA, Harun S. Construction of a polycystic ovarian syndrome (PCOS) pathway based on the interactions of PCOS-related proteins retrieved from bibliomic data. Theor Biol Med Model 2009; 6: 18.
  • 47
    Gharani N, Waterworth DM, Batty S, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Molec Genet 1997; 6: 397402.
  • 48
    Wood JR, Nelson-Degrave VL, Jansen E, et al. Valproate-induced alterations in human theca cell gene expression: clues to the association between valproate use and metabolic side effects. Physiol Genomics 2005; 20: 23343.
  • 49
    Viger RS, Guittot SM, Anttonen M, Wilson DB, Heikinheimo M. Role of the GATA family of transcription factors in endocrine development, function, and disease. Mol Endocrinol 2008; 22: 78198.
  • 50
    Toda K, Okada T, Miyaura C, Saibara T. Fenofibrate, a ligand for PPARalpha, inhibits aromatase cytochrome P450 expression in the ovary of mouse. J Lipid Res 2003; 44: 26570.
  • 51
    Forcheron F, Abdallah P, Basset A, del Carmine P, Haffar G, Beylot M. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. Obesity (Silver Spring) 2009; 17: 13819.
  • 52
    Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Strauss JF III, McAllister JM. Differential activity of the cytochrome P450 17-alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocr Metab 2000; 85: 230411.
  • 53
    McAllister JM. Conditions for functional, long-term human theca interna and granulosa cell cultures from polycystic ovaries. Endocrinology 1995; 136: 1439.
  • 54
    Echiburú B, Pérez-Bravo F, Maliqueo M, Sánchez F, Crisosto N, Sir-Petermann T. Polymorphism T --> C (-34 base pairs) of gene CYP17 promoter in women with polycystic ovary syndrome is associated with increased body weight and insulin resistance: a preliminary study. Metabolism 2008; 57: 176571.
  • 55
    Lagaly DV, Aad PY, Grado-Ahuir JA, Hulsey LB, Spicer LJ. Role of adiponectin in regulating ovarian theca and granulosa cell function. Mol Cell Endocrinol 2008; 284: 3845.
  • 56
    Gambineri A, Forlani G, Munarini A. Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. J Endocrinol Invest 2009; 32: 2108.
  • 57
    Stewart PM, Shackleton CHL, Beastall GH, Edwards CRW. 5-Alpha-reductase activity in polycystic ovary syndrome. Lancet 1990; 335: 4313.
  • 58
    Jakimiuk AJ, Weitsman SR, Magoffin DA. 5-alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocr Metab 1999; 84: 24148.
  • 59
    Vassiliadi DA, Barber TM, Hughes BA, et al. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94: 355866.
  • 60
    Glintborg D, Hermann AP, Hagen C, et al. A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome. Fertil Steril 2009; 91: 84250.
  • 61
    Tomlinson JW, Finney J, Hughes BA, Hughes SV, Stewart PM. Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss. Diabetes 2008; 57: 153643.
  • 62
    Westerbacka J, Yki-Järvinen H, Vehkavaara S, et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 2003; 88: 492431.
  • 63
    Toprak S, Yönem A, Cakir B, et al. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm Res 2001; 55: 6570.
  • 64
    Carlström K, Eriksson S, Rannevik G. Sex steroids and steroid binding proteins in female alcoholic liver disease. Acta Endocrinol (Copenh) 1986; 111: 759.
  • 65
    Buchanan G, Ricciardelli C, Harris JM, et al. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res 2007; 67: 1008796.
  • 66
    Winnefeld M, Grewenig A, Schnölzer M, et al. Human SGT interacts with Bag-6/Bat-3/Scythe and cells with reduced levels of either protein display persistence of few misaligned chromosomes and mitotic arrest. Exp Cell Res 2006; 312: 250014.
  • 67
    Yin H, Wang H, Zong H, et al. SGT, a Hsp90beta binding partner, is accumulated in the nucleus during cell apoptosis. Biochem Biophys Res Commun 2006; 343: 11538.
  • 68
    Hughes C, Elgasim M, Layfield R, Atiomo W. Genomic and post-genomic approaches to polycystic ovary syndrome – progress so far: mini Review. Hum Reprod 2006; 21: 276675.
  • 69
    Younossi ZM, Baranova A, Stepanova M, et al. Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis. J Proteome Res 2010; 9: 321824.
  • 70
    Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93: 1628.
  • 71
    Wu Q, Saunders RA, Szkudlarek-Mikho M, Serna ID, Chin KV. The obesity-associated Fto gene is a transcriptional coactivator. Biochem Biophys Res Commun 2010; 401: 3905.
  • 72
    Church C, Lee S, Bagg EA, et al. A mouse model for the metabolic effects of the human fat mass and obesity associated FTO gene. PLoS Genet 2009; 5: e1000599.
  • 73
    Wehr E, Schweighofer N, Möller R, Giuliani A, Pieber TR, Obermayer-Pietsch B. Association of FTO gene with hyperandrogenemia and metabolic parameters in women with polycystic ovary syndrome. Metabolism 2010; 59: 57580.
  • 74
    Barber TM, Bennett AJ, Groves CJ, et al. Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. Diabetologia 2008; 51: 11538.
  • 75
    Bravard A, Lefai E, Meugnier E, et al. FTO is increased in muscle during type 2 diabetes and its over-expression in myotubes alters insulin signalling,enhances lipogenesis and ROS production, and induces mitochondrial dysfunction. Diabetes 2011; 60: 25868.
  • 76
    Skov V, Glintborg D, Knudsen S, et al. Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. Diabetes 2007; 56: 234955.
  • 77
    Reed MJ, Meszaros K, Entes LJ, et al. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of Type II diabetes. Diabetologia 1999; 42: 1026.
  • 78
    Chen M, Yang ZD, Smith KM, Carter JD, Nadler JL. Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity. Diabetologia 2005; 48: 48695.
  • 79
    McDuffie M, Maybee NA, Keller SR, et al. Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes. Diabetes 2008; 57: 199208.
  • 80
    Martínez-Clemente M, Ferré N, Titos E, et al. Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. Hepatology 2010; 52: 198091.
  • 81
    Maher JF, Hines RS, Futterweit W, et al. FEM1A is a candidate gene for polycystic ovary syndrome. Gynecol Endocrinol 2005; 21: 3305.
  • 82
    Goodarzi MO, Maher JF, Cui J, Guo X, Taylor KD, Azziz R. FEM1A and FEM1B: novel candidate genes for polycystic ovary syndrome. Hum Reprod 2008; 23: 28429.
  • 83
    Takayama K, Sukhova GK, Chin MT, Libby P. A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling. Circ Res 2006; 98: 499504.
  • 84
    Mal’tsev AN, Levé OI, Sadovnichiĭ VV, Buko VU. Antioxidant effect of prostaglandin E2 in the liver alcoholic steatosis. Eksp Klin Farmakol 2001; 64: 613.
  • 85
    Rincón-Sánchez AR, Covarrubias A, Rivas-Estilla AM, et al. PGE2 alleviates kidney and liver damage, decreases plasma renin activity and acute phase response in cirrhotic rats with acute liver damage. Exp Toxicol Pathol 2005; 56: 291303.
  • 86
    Minami M, Shimizu K, Okamoto Y, et al. Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation. J Biol Chem 2008; 283: 9692703.
  • 87
    Douroudis K, Kisand K, Nemvalts V, Rajasalu T, Uibo R. Allelic variants in the PHTF1-PTPN22, C12orf30 and CD226 regions as candidate susceptibility factors for the type 1 diabetes in the Estonian population. BMC Med Genet 2010; 11: 11.
  • 88
    Subauste MC, Sansom OJ, Porecha N, Raich N, Du L, Maher JF. Fem1b, a proapoptotic protein, mediates proteasome inhibitor-induced apoptosis of human colon cancer cells. Mol Carcinog 2010; 49: 10513.
  • 89
    Sun TP, Shieh SY. Human FEM1B is required for Rad9 recruitment and CHK1 activation in response to replication stress. Oncogene 2009; 28: 197181.
  • 90
    Lu D, Ventura-Holman T, Li J, McMurray RW, Subauste JS, Maher JF. Abnormal glucose homeostasis and pancreatic islet function in mice with inactivation of the Fem1b gene. Mol Cell Biol 2005; 25: 65707.
  • 91
    Tziomalos K, Dimitroula HV, Katsiki N, Savopoulos C, Hatzitolios AI. Effects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inflammation in obese patients. Mediators Inflamm 2010; 2010: 364957.
  • 92
    Kelly CCJ, Lyall H, Petrie JR, Gould GW, Connell JMC, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 24535.
  • 93
    Oh JY, Lee JA, Lee H, Oh JY, Sung YA, Chung H. Serum C-reactive protein levels in normal-weight polycystic ovary syndrome. Korean J Intern Med 2009; 24: 3505.
  • 94
    Amato G, Conte M, Mazziotti G, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 2003; 101: 117782.
  • 95
    Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005; 90: 601421.
  • 96
    Yoneda M, Mawatari H, Fujita K, et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007; 42: 57382.
  • 97
    Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 41221.
  • 98
    Wickham EP 3rd, Cheang KI, Clore JN, Baillargeon JP, Nestler JE. Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome. Metabolism 2010 [Epub ahead of print].
  • 99
    Wilcox G. Insulin and insulin resistance. Clin Biochem Rev 2005; 26: 1939.
  • 100
    Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2007; 3: 10311.
  • 101
    Okamoto H, Accili D. In vivo mutagenesis of the insulin receptor. J Biol Chem 2003; 278: 2835962.
  • 102
    Tucci S, Futterweit W, Concepcion ES, et al. Evidence for association of polycystic ovary syndrome in Caucasian women with a marker at the insulin receptor gene locus. J Clin Endocr Metab 2001; 86: 4469.
  • 103
    Siegel S, Futterweit W, Davies TF, et al. A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril 2002; 78: 12403.
  • 104
    Ioannidis A, Ikonomi E, Dimou NL, Douma L, Bagos PG. Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: a Mendelian randomization meta-analysis. Mol Genet Metab 2010; 99: 17483.
  • 105
    Allemand MC, Irving BA, Asmann YW, et al. Effect of testosterone on insulin stimulated IRS1 Ser phosphorylation in primary rat myotubes – a potential model for PCOS-related insulin resistance. PLoS ONE 2009; 4: e4274.
  • 106
    Taniguchi CM, Ueki K, Kahn R. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 2005; 115: 71827.
  • 107
    Ishiki M, Klip A. Minireview: recent developments in the regulation of glucose transporter-4 traffic: new signals, locations, and partners. Endocrinology 2005; 146: 50718.
  • 108
    Chang L, Chiang SH, Saltiel AR. Insulin signaling and the regulation of glucose transport. Mol Med 2004; 10: 6571.
  • 109
    Goodarzi MO, Jones MR, Chen YD, Azziz R. First evidence of genetic association between AKT2 and polycystic ovary syndrome. Diab Care 2008; 31: 22847.
  • 110
    Goto M, Iwase A, Ando H, et al. PTEN and Akt expression during growth of human ovarian follicles. J Assist Reprod Genet 2007; 24: 5416.
  • 111
    He L, Hou X, Kanel G, et al. The critical role of AKT2 in hepatic steatosis induced by PTEN loss. Am J Pathol 2010; 176: 23028.
  • 112
    Semple RK, Sleigh A, Murgatroyd PR, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 2009; 119: 31522.
  • 113
    Leavens KF, Easton RM, Shulman GI, Previs SF, Birnbaum MJ. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab 2009; 10: 40518.
  • 114
    Jensterle M, Janez A, Mlinar B, Marc J, Prezelj J, Pfeifer M. Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur J Endocrinol 2008; 158: 793801.
  • 115
    Gawrieh S, Baye TM, Carless M. Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg 2010; 20: 1698709.
  • 116
    Katsiki N, Hatzitolios AI. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. Curr Opin Obstet Gynecol 2010; 22: 46676.
  • 117
    Pasquali R, Gambineri AG, Cavazza C, et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol 2011; 164: 5360.
  • 118
    Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006; 21: 809.
  • 119
    Maggard MA, Yermilov I, Li Z, et al. Pregnancy and fertility following bariatric surgery: a systematic review. JAMA 2008; 300: 228696.
  • 120
    Teitelman M, Grotegut CA, Williams NN, Lewis JD. The impact of bariatric surgery on menstrual patterns. Obes Surg 2006; 16: 145763.
  • 121
    Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millan JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005; 90: 63649.
  • 122
    Brewer CJ, Balen AH. The adverse effects of obesity on conception and implantation. Reproduction 2010; 140: 34764.
  • 123
    Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79104.
  • 124
    Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 1219.
  • 125
    Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; 20: CD007340.
  • 126
    Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis 2010; 28: 2749.